Quest Diagnostics (NYSE:DGX) Given New $154.00 Price Target at Robert W. Baird
Quest Diagnostics (NYSE:DGX – Free Report) had its price target hoisted by Robert W. Baird from $153.00 to $154.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the medical research company’s stock. Several other analysts have also weighed in on the company. Barclays upped […]
More Stories
Bitgert (BRISE) Price Down 0.8% This Week
Bitgert (BRISE) traded up 5.3% against the dollar during the one day period ending at 23:00 PM E.T. on October...
Financial Contrast: Glucose Health (GLUC) vs. Its Peers
Glucose Health (OTCMKTS:GLUC – Get Free Report) is one of 53 public companies in the “Medicinals & botanicals” industry, but...
JUNO (JUNO) Self Reported Market Cap Tops $7.06 Million
JUNO (JUNO) traded down 0.6% against the US dollar during the 24-hour period ending at 23:00 PM Eastern on October...
Relay Token (RELAY) Tops 1-Day Volume of $0.03
Relay Token (RELAY) traded flat against the dollar during the 1 day period ending at 23:00 PM E.T. on October...
SafeMoon V2 (SFM) Price Hits $0.0000 on Major Exchanges
SafeMoon V2 (SFM) traded down 2.3% against the US dollar during the 1 day period ending at 23:00 PM ET...
Apu Apustaja Self Reported Market Cap Tops $296.37 Million (APU)
Apu Apustaja (APU) traded 10.3% higher against the U.S. dollar during the one day period ending at 23:00 PM Eastern...